Case report · 10 Aug 2026
Conference abstractPublished 28 Mar 2019
Integrating regulatory drug label information to facilitate evaluation of adverse events in pharmacovigilance
AstraZeneca, USA
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
Pharmacovigilance (PV) is the science and activity in detection, evaluation, and management of Adverse Events (AE) reported for medicinal products. In either clinical trials or post-marketing surveillance, qualitative and quantitative methods have been developed to identify the AEs that are associated with the target drug, and further evaluations are carried out to determine whether the drug has likely caused the AEs before decisions can be made on the management of them â?? once confirmed, an AE is termed Adverse Drug Reaction. This process which requires expertise from trained scientists and physicians is very resource intensive because there are often many AEs in a study case or spontaneous individual case safety report, as well as many interfering Concomitant Medications (CM) that might have contributed to the reported AEs. This article introduces a systemic approach to extract those case CMs that are Known Implicating Medications for each AE according to public regulatory information from drug labels â?? FDA Structured Product Labeling or EMA Summary of Product Characteristics. This makes critical information readily available for users to discern possible interferences from CM and make informed decisions on the evaluation of the AE â?? saving time while improving quality. In the future, it’s expected that this concept and automation will be fully integrated into commercial signal detection and management software packages so that they will be easily accessible and may even lead to reduced False Positive rate in signal detection for PV industry.
Subjects
Pharmaceutical SciencesAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
More from this journal
The newest in Journal of Clinical Trials.
Short communication · 31 Jul 2026
Understanding Bioavailability as a Key Element in Effective Therapeutic Delivery
Research article · 14 Jun 2026
Ensuring Rights and Dignity in Ethical Practices of Clinical Studies with Vulnerable Group and Safeguarding Vulnerable Group Act (2006)
Conferences in this field
Upcoming conferences in this field.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalJournal of Clinical Trials
- SubjectPharmaceutical Sciences
- BylineArticles whose byline prints “Zhou (Tom) Hui”
